反应 #1726710

ord-cfe4896ea39641d6b135935f967bdf42

反应方程式

O=C1CCNCC1
4-piperidone
COc1ccc(O)c(C(N)=O)c1
2-hydroxy-5-methoxybenzamide
C1COCCN1
morpholine
COc1ccc2c(c1)C(=O)NC1(CCNCC1)O2
Compound 150
COc1ccc2c(c1)C(=O)NC1(CCNCC1)O2
6-methoxyspiro-[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one

反应条件

详细条件
See reaction.notes.procedure_details.

后处理

  1. 1
    温度is refluxed for 20 hr
  2. 2
    洗涤washed with water, brine
  3. 3
    干燥dried over Na2SO4
  4. 4
    其他After solvent removal by rotoevaporation
  5. 5
    其他the crude product is purified by preparative TLC

实验过程

A mixture of 26 mg (0.083 mmol) of N-[4,8-dimethoxyquinoline-2-yl)carbonyl]-4-piperidone (prepared as described in Example 44), 14 mg (0.083 mmol) of 2-hydroxy-5-methoxybenzamide, and 0.020 mL of morpholine in a mixture of 0.2 mL of toluene and 0.6 mL of methanol is refluxed for 20 hr. The reaction mixture is diluted with ethyl acetate, and washed with water, brine, and dried over Na2SO4. After solvent removal by rotoevaporation, the crude product is purified by preparative TLC to give 17 mg (0.037 mmol, 45% yield) of 1′-[4,8-dimethoxyquinoline-2-yl)carbonyl]-6-methoxyspiro-[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one (Compound 150): 1H NMR (DMSO-d6): δ 3.76 (s, 3H), 3.95 (s, 3H), 4.07 (s, 3H), 7.04 (d, 1H), 7.12 (d of d, 1H), 7.19 (s, 1H), 7.24 (m, 2H), 7.52 (d of d, 1H), 7.68 (d, 1H), and 8.85 ppm (s, 1H). MS m/z: 464.1 (M+H)+, 486.2 (M+Na)+.

来源

DOI: 10.6084/m9.figshare.5104873.v1专利: US08110570B2uspto-grants-2012_02